LOS ANGELES, Calif. – April 27, 2026 (NEWMEDIAWIRE) – Cardiovascular disease remains one of the most serious and costly health challenges worldwide, and early detection and more precise, personalized treatment strategies are urgently needed. Cardio Diagnostics Holdings (NASDAQ: CDIO) is focused on addressing this need by leveraging artificial intelligence (“AI”) and multi-omics biomarkers to develop advanced solutions that provide actionable insights from simple blood samples and enable more informed and timely cardiac care decisions.
- The scale and impact of cardiovascular disease highlights why innovation in this field is so important.
- Advances in genomics and epigenetics have enabled us to better understand how genetic predisposition and environmental influences interact to promote disease progression.
- Cardio Diagnostics lowers the barrier to advanced cardiovascular testing through the use of simple blood tests.
The scale and impact of cardiovascular disease highlights why innovation in this field is so important. According to the Centers for Disease Control and Prevention, heart disease remains the leading cause of death in the United States, killing about one in three people. Beyond death…
read more
Please see the full Terms of Use and Disclaimer for the InvestorBrandNetwork website, which applies to all content provided by IBN, whether published or republished: http://IBN.fm/Disclaimer
The latest news and updates about CDIO are available in the company’s newsroom at https://ibn.fm/CDIO.
Forward-looking statements
Certain statements in this article are forward-looking as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties and other factors that could cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to numerous risks and uncertainties, including various factors that are beyond management’s control. This includes the risks described under the heading “Risk Factors” in Part 1 of our most recent Annual Report on Form 10-K under the heading “Item 1A. Risk Factors” or current information described in Part 2 of our Quarterly Reports under the heading “Item 1A. Risk Factors.” as described in our Form 10-Q and our other filings with the SEC. You should not place undue reliance on the forward-looking statements in this article when making investment decisions. These statements are based on information available as of the date of this document. All parties undertake no obligation to update this information unless required by law.
See the original release at www.newmediawire.com
